April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.

A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.